OXT and obesity due to melanocortin 4 receptor deficiency: Human studies are currently ongoing to assess the promise of oxytocin as a therapeutic agent and to evaluate the potential involvement of disrupted oxytocin actions in the pathophysiology of obesity and metabolic syndrome.